Literature DB >> 30850754

The number of positive confirmatory tests is associated with the clinical presentation and incidence of cardiovascular and cerebrovascular events in primary aldosteronism.

Aya Saiki1, Daisuke Tamada1, Reiko Hayashi1, Kosuke Mukai1, Tetsuhiro Kitamura1, Mitsuyoshi Takahara1, Michio Otsuki2, Iichiro Shimomura1.   

Abstract

Primary aldosteronism (PA) is a major cause of secondary hypertension and presents a higher risk for cardio-cerebrovascular (CCV) events compared with essential hypertension. To diagnose PA after a positive screening test, at least one of three available confirmatory tests [the saline infusion test (SIT), the captopril challenge test (CCT) or the furosemide upright test (FUT)] should be performed. The aim of our study was to investigate the relationship between the number of positive confirmatory tests using SIT and CCT and the clinical presentation and prevalence of CCV events in 398 PA patients. The number of PA patients doubled when PA diagnosis was defined by positive results on either the SIT or CCT confirmatory tests (single positive) compared to positive results on both the SIT and CCT confirmatory tests (double positive). We also found a more typical clinical presentation of PA, such as the use of more antihypertensive drugs to control blood pressure and a higher incidence of hypokalemia, in PA patients with double positive confirmatory tests than in those with a single positive confirmatory test. The incidence of CCV events in PA patients with double positive confirmatory tests was significantly higher than that in those with a single positive confirmatory test. Our results demonstrated that the number of PA patients was doubled by the use of PA diagnostic criteria using a single positive confirmatory test compared to the use of double positive confirmatory tests. PA patients with double positive confirmatory tests were associated with a more typical clinical presentation and a higher incidence of CCV events than those with a single positive confirmatory test.

Entities:  

Keywords:  Captopril challenge test (CCT); Cardiovascular and cerebrovascular (CCV) events; Primary aldosteronism (PA); Saline infusion test (SIT)

Mesh:

Year:  2019        PMID: 30850754     DOI: 10.1038/s41440-019-0247-1

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  5 in total

1.  Comparison of the shortened and standard saline infusion tests for primary aldosteronism diagnostics.

Authors:  Kaoru Yamashita; Midori Yatabe; Yasufumi Seki; Kanako Bokuda; Daisuke Watanabe; Satoru Shimizu; Satoshi Morimoto; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-05-08       Impact factor: 3.872

2.  Performance of Confirmatory Tests for Diagnosing Primary Aldosteronism: a Systematic Review and Meta-Analysis.

Authors:  Alexander A Leung; Christopher J Symonds; Gregory L Hundemer; Paul E Ronksley; Diane L Lorenzetti; Janice L Pasieka; Adrian Harvey; Gregory A Kline
Journal:  Hypertension       Date:  2022-06-02       Impact factor: 9.897

3.  Oral Salt Loading Test is Associated With 24-Hour Blood Pressure and Organ Damage in Primary Aldosteronism Patients.

Authors:  Yuichi Yoshida; Saki Yoshimura; Mizuki Kinoshita; Yoshinori Ozeki; Mitsuhiro Okamoto; Koro Gotoh; Takayuki Masaki; Hirotaka Shibata
Journal:  J Endocr Soc       Date:  2020-08-24

4.  Effect of Yiqi Huayu Pinggan Zishen Formula Combined with Valsartan in the Treatment of Hypertension and Its Effect on MMP-9, Ang II, and MCP-1.

Authors:  Jing Yan; Defeng Li; Qin Liu; Yuanlan Xie
Journal:  Comput Math Methods Med       Date:  2022-05-06       Impact factor: 2.809

5.  Basal Plasma Aldosterone Concentration Predicts Therapeutic Outcomes in Primary Aldosteronism.

Authors:  Aya Saiki; Michio Otsuki; Kosuke Mukai; Reiko Hayashi; Iichiro Shimomura; Isao Kurihara; Takamasa Ichijo; Yoshiyu Takeda; Takuyuki Katabami; Mika Tsuiki; Norio Wada; Yoshihiro Ogawa; Junji Kawashima; Masakatsu Sone; Nobuya Inagaki; Takanobu Yoshimoto; Ryuji Okamoto; Katsutoshi Takahashi; Hiroki Kobayashi; Kouichi Tamura; Kohei Kamemura; Koichi Yamamoto; Shoichiro Izawa; Miki Kakutani; Masanobu Yamada; Akiyo Tanabe; Mitsuhide Naruse
Journal:  J Endocr Soc       Date:  2020-02-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.